Wall Street analyst estimates for Cyclerion Therapeutics, Inc. (CYCN): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Cyclerion Therapeutics, Inc. operates as a biopharmaceutical company in the clinical development phase, concentrating on the discovery, advancement, and commercialization of therapeutic agents for debilitating central nervous system (CNS) disorders. Their leading experimental compound, CY6463, is a soluble guanylate cyclase (sGC) stimulator designed to cross the blood-brain barrier.
Valuation Ratios
| Price / Book | 2.81 |
| EV / EBITDA | -2.14 |
| Dividend Yield | 0.00% |
Price
| Price | $23.52 |
| Market Cap | $16M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ADXN · AIM · KTTA · NBY · PLRZ · QNRX · RADX
Explore sector: Healthcare · Biotechnology
More sections of CYCN: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks